We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Medcohealth Solutions Common Stock | NYSE:MHS | NYSE | Ordinary Share |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 70.30 | 0.00 | 01:00:00 |
From Jul 2019 to Jul 2024
French pharmaceutical group Sanofi SA (SAN.FR) said Wednesday it signed an agreement with Medco Health Solutions Inc (MHS) and its unit United BioSource Corp., or UBC, to better leverage the real-world evidence generated during product development and throughout the product lifecycle in order to improve the overall quality of patient care.
MAIN FACTS:
- Under the terms of this multi-year agreement, Medco and UBC will provide real-world input and comparative data into product development strategy.
- This agreement will allow Sanofi to define the relative value for products early in development, by more precisely identifying patient populations in which drugs are most effective.
- It will also enable Sanofi to maximize the full value potential of R&D innovation through early alignment of patient population assessments, payer and medical needs. The objective is to develop integrated solutions for patients by implementing novel care models and to improve adherence and patient outcomes.
- Sanofi didn't release any financial details on the agreement with Medco.
- By Paris Bureau, Dow Jones Newswires; +331-4017-1740; inti.landauro@dowjones.com
1 Year Medco Chart |
1 Month Medco Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
